Editas Medicine Inc (EDIT)vsBeiGene, Ltd. (ONC)
EDIT
Editas Medicine Inc
$2.70
+1.89%
HEALTHCARE · Cap: $469.95M
ONC
BeiGene, Ltd.
$346.51
+1.38%
HEALTHCARE · Cap: $40.53B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 12939% more annual revenue ($6.13B vs $47.01M). ONC leads profitability with a 10.7% profit margin vs -157.3%. ONC earns a higher WallStSmart Score of 64/100 (C+).
EDIT
Avoid31
out of 100
Grade: F
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EDIT.
Margin of Safety
+80.1%
Fair Value
$1767.21
Current Price
$346.51
$1420.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 232.3% year-over-year
Conservative balance sheet, low leverage
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -70.2% — below average capital efficiency
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : EDIT
The strongest argument for EDIT centers on Revenue Growth, Debt/Equity. Revenue growth of 232.3% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.
Bear Case : EDIT
The primary concerns for EDIT are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.1x leaves little room for execution misses.
Key Dynamics to Monitor
EDIT profiles as a hypergrowth stock while ONC is a growth play — different risk/reward profiles.
EDIT carries more volatility with a beta of 2.06 — expect wider price swings.
EDIT is growing revenue faster at 232.3% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (64/100 vs 31/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Editas Medicine Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?